Semaglutide Research: Weight Loss, Heart and Kidney Outcomes

Semaglutide deserves a more precise description than a weight-loss percentage. Our assessment is that its evidence should be organized around the condition being treated, the formulation tested and the outcome measured. A useful profile should help you distinguish substantial clinical evidence from claims that stretch beyond the study.

This guide examines selected randomized trials, a withdrawal extension and current US prescribing information. Use it to understand research and prepare questions for a clinician. It is not an individualized treatment plan or a complete catalog of semaglutide studies.

What is semaglutide, and why do the product names matter?

Semaglutide is a GLP-1 receptor agonist. The June 2026 Wegovy label covers both injection and tablets, with different indication details. Wegovy prescribing information.

Start your research notes with three fields: active ingredient, named product and route. Then add the indication and population. Our recommendation is to keep those fields attached to every claim, including claims about approved uses.

The May 2026 Ozempic label includes glycemic control in adults with type 2 diabetes, cardiovascular-event risk reduction in adults with diabetes and established cardiovascular disease, and specified kidney and cardiovascular risk reduction in adults with diabetes and chronic kidney disease. Ozempic prescribing information.

Our interpretation: the shared ingredient does not justify replacing a product-specific label with an unrestricted list of benefits. When comparing an online listing with a clinical paper, also require evidence about the actual preparation. Read our molecular-identity guide for the difference between recognizing a name and verifying a material.

What does the current Wegovy label cover?

Both formulations have adult weight-management and cardiovascular indications in defined populations. Weight eligibility includes obesity, or overweight with a weight-related condition; cardiovascular eligibility requires established cardiovascular disease with overweight or obesity. Injection also includes obesity treatment from age 12. Its adult noncirrhotic MASH indication is limited to moderate-to-advanced fibrosis, stages F2-F3, under accelerated approval; confirmation of clinical benefit remains required. The tablet indications do not include pediatric obesity or MASH. Current Wegovy label.

Our reading advice: avoid shortening these details to “approved for liver disease” or “approved for heart health.” Ask which diagnosis, which stage and which product the statement means. For MASH in particular, retain the confirmation requirement when discussing the approval.

The label is the starting point for an approval question; a trial paper is the starting point for understanding how a result was obtained. We recommend reading both rather than treating either as a substitute for the other.

An evidence map for the main research questions

This original map organizes questions. It is not a scale of treatment effects or an experimental figure.

Use the map to challenge a broad benefit claim. For example, ask whether a weight result is being used to imply an unmeasured cardiovascular outcome, or whether a result during treatment is being presented as permanent after withdrawal.

STEP 1: how much weight loss was observed?

STEP 1 randomized 1,961 adults without diabetes to semaglutide 2.4 mg or placebo, alongside lifestyle intervention, for 68 weeks. Mean weight change was -14.9% versus -2.4%; the published adjusted difference was -12.4 percentage points, with a 95% confidence interval of -13.4 to -11.5. Original STEP 1 trial.

Our interpretation: this supports a substantial average treatment effect in the studied setting. Keep “average” in the sentence. Do not translate it into a promised result for a particular reader or an expectation after only a few weeks.

For a fair comparison, record the study duration, eligibility criteria and comparator alongside the percentage. Use the reported statistical estimate rather than trying to reconstruct an adjusted treatment effect from rounded headline values. Our weight-trial comparison guide explains how to keep unlike studies separate.

SELECT: cardiovascular events in people without diabetes

SELECT enrolled 17,604 people with established cardiovascular disease and overweight or obesity, without diabetes. Over a mean 39.8-month follow-up, the cardiovascular composite occurred in 6.5% with semaglutide and 8.0% with placebo. The hazard ratio was 0.80, with a 95% confidence interval of 0.72 to 0.90. The composite included cardiovascular death, nonfatal heart attack or nonfatal stroke. Adverse events led to permanent treatment discontinuation in 16.6% versus 8.2%. SELECT publication.

Our interpretation: distinguish the relative time-to-event result from the difference between the observed event proportions. Do not describe the finding as a 20-percentage-point absolute reduction. Also retain the preexisting cardiovascular disease requirement when explaining whom the trial studied.

Our recommendation is to discuss benefit and treatment burden together. The discontinuation result belongs beside the benefit, because a review focused entirely on efficacy leaves out part of the clinical decision.

FLOW: a separate kidney-outcomes question

FLOW randomized 3,533 participants with type 2 diabetes and chronic kidney disease. The primary composite included kidney failure, a substantial decline in estimated kidney filtration, or kidney-related or cardiovascular death. There were 331 first events with semaglutide and 410 with placebo, corresponding to a hazard ratio of 0.76, with a 95% confidence interval of 0.66 to 0.88. Median follow-up was 3.4 years; early stopping followed a prespecified interim analysis. FLOW original report.

Our interpretation: describe the composite explicitly rather than saying every participant’s kidney function improved. A composite event result should not be rewritten as kidney regeneration. Keep the diabetes and chronic-kidney-disease population attached to the conclusion.

Oral semaglutide: what SOUL adds

SOUL studied 9,650 people with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease or both. Oral semaglutide was compared with placebo. Over a mean 47.5 months, major cardiovascular events occurred in 12.0% versus 13.8%, hazard ratio 0.86, with a 95% confidence interval of 0.77 to 0.96. Confirmatory secondary outcomes did not differ significantly. SOUL original trial.

Our interpretation: this provides route-specific clinical evidence. Do not use it as a head-to-head comparison with an injectable formulation or as proof that every secondary outcome improved. Match the formulation and trial question before combining conclusions from different research programs.

What happened after semaglutide was stopped?

The STEP 1 extension analyzed 327 participants after medication and structured lifestyle intervention ended at week 68. In the semaglutide group, the earlier mean loss was 17.3%; over the following year, participants regained 11.6 percentage points relative to starting weight, leaving a net 5.6% loss. The extension analyses were exploratory. Original extension publication.

Our interpretation: this is important maintenance evidence, but it is not a randomized comparison of continuing versus stopping treatment. Preserve the smaller subset and the simultaneous withdrawal of lifestyle support. Do not describe it as proof of one inevitable trajectory for everyone.

Before starting a treatment discussion, ask how progress, tolerability and a possible interruption would be managed. We recommend making maintenance part of the initial conversation rather than waiting until a prescription or coverage arrangement changes.

How does semaglutide compare with tirzepatide?

In SURMOUNT-5, 751 adults with obesity without diabetes were randomized in an open-label, 72-week comparison. Mean weight change favored tirzepatide over semaglutide, -20.2% versus -13.7%, using the trial’s maximum tolerated regimens. Original comparison.

Our interpretation: use a direct comparison for the question it tested. Do not turn superiority on weight in one protocol into superiority for every diagnosis, safety outcome or available formulation. Read the tirzepatide profile for the comparator details and separate diabetes evidence.

What safety issues belong in a serious review?

Ozempic’s boxed warning concerns rodent thyroid C-cell tumors; human relevance is unknown. Personal or family medullary thyroid carcinoma and MEN2 are contraindications. Its warnings also address pancreatitis, gallbladder disease, severe gastrointestinal reactions, dehydration-related kidney injury, diabetic retinopathy complications, hypoglycemia with certain diabetes medicines, and aspiration around anesthesia or deep sedation. Prescribing information.

Use the exact product’s full label and medication guide with a clinician. Bring the medication list, relevant history, pregnancy plans and upcoming procedures to that discussion. This selected summary should not be used to screen yourself into treatment or decide that a symptom is harmless.

Questions to bring to a clinician or use when checking a claim

• Which diagnosis and formulation is this recommendation addressing?
• Which trial most closely matches the person’s health context?
• Is the claimed benefit a weight change, laboratory measure or clinical event?
• What would count as meaningful progress, and when would it be reassessed?
• How will adverse effects, other medicines and interruptions be handled?
• What evidence supports the exact preparation being supplied?

Our assessment is that a good semaglutide explanation should let a reader answer these questions without relying on a brand slogan. Favor a documented clinical pathway and clearly described evidence over a universal promise about weight, longevity or metabolic optimization.

Sources and editorial scope

The links above lead to current product information and original research records. This is a selected narrative review, with source checks dated September 13, 2026. Some original abstracts were accessed through indexed PubMed text. The STEP 1 extension was checked against the original open-access publisher PDF hosted by a clinic after direct publisher and PMC access failed.